DNA Viral Infections Complicating Lung Transplantation

Abstract

DNA viruses with potential to cause complications after lung transplantation include the human Herpesviridae family consisting of cytomegalovirus (CMV), herpes simplex virus 1 and 2 (HSV-1, -2), varicella-zoster virus (VZV), human herpesvirus 6, 7, and 8 (HHV-6, -7, -8), and Epstein-Barr virus (EBV); the Polyomaviridae family consisting of BK virus and JC virus; and the Adenoviridae family consisting of more than 50 adenovirus subtypes. This is a diverse group of viruses with equally diverse immediate and long-term impacts on allograft function and clinical outcomes following lung transplantation. This article discusses the individual pathogens, their epidemiology and clinical manifestations, as well as treatment and preventive strategies in this era of antiviral treatment regimens.

Keywords

DNA viruses - viral infection - lung transplantation

• References

• 1 Christie JD, Edwards LB, Kucheryavaya AY , et al; International Society of Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31 (10) 1073-1086
• 2 Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990; 12 (Suppl. 07) S701-S710
• 3 Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ 1973; 49 (1) 103-106
• 4 Söderberg-Nauclér C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91 (1) 119-126
• 5 Chou SW. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 1986; 314 (22) 1418-1423
• 6 Lowance D, Neumayer HH, Legendre CM , et al; International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340 (19) 1462-1470
• 7 Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34 (8) 1094-1097
• 8 Gane E, Saliba F, Valdecasas GJ , et al; The Oral Ganciclovir International Transplantation Study Group. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350 (9093) 1729-1733
• 9 Sagedal S, Hartmann A, Nordal KP , et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66 (1) 329-337
• 10 Linares L, Sanclemente G, Cervera C , et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc 2011; 43 (6) 2145-2148
• 11 Humar A, Lebranchu Y, Vincenti F , et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10 (5) 1228-1237
• 12 Paya C, Humar A, Dominguez E , et al; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4 (4) 611-620
• 13 Humar A, Snydman D. AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl. 04) S78-S86
• 14 Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22 (2) 162-170
• 15 Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005; 40 (5) 704-708
• 16 Palmer SM, Limaye AP, Banks M , et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152 (12) 761-769
• 17 Arthurs SK, Eid AJ, Pedersen RA , et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46 (6) 840-846
• 18 Blyth D, Lee I, Sims KD , et al. Risk factors and clinical outcomes of cytomegalovirus disease occurring more than one year post solid organ transplantation. Transpl Infect Dis 2012; 14 (2) 149-155
• 19 Limaye AP, Bakthavatsalam R, Kim HW , et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81 (12) 1645-1652
• 20 Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357 (25) 2601-2614
• 21 Lautenschlager I, Halme L, Höckerstedt K, Krogerus L, Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 2006; 8 (1) 21-30
• 22 Snydman DR, Limaye AP, Potena L, Zamora MR. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 2011; 43 (3, Suppl): S1-S17
• 23 Peleg AY, Husain S, Kwak EJ , et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44 (2) 204-212
• 24 Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant 2007; 21 (3) 309-313
• 25 Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008; (2) CD003774
• 26 Hodson EM, Jones CA, Webster AC , et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365 (9477) 2105-2115
• 27 George MJ, Snydman DR, Werner BG , et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103 (2) 106-113
• 28 Walker RC, Marshall WF, Strickler JG , et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20 (5) 1346-1353
• 29 Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185 (3) 273-282
• 30 Estenne M, Maurer JR, Boehler A , et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21 (3) 297-310
• 31 Evans PC, Soin A, Wreghitt TG, Taylor CJ, Wight DG, Alexander GJ. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000; 69 (1) 30-35
• 32 Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Häyry PJ, Lemström KB. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis 1999; 1 (2) 115-126
• 33 Nett PC, Heisey DM, Fernandez LA, Sollinger HW, Pirsch JD. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004; 78 (7) 1036-1041
• 34 Erdbruegger U, Scheffner I, Mengel M , et al. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant 2012; 27 (1) 435-443
• 35 Kranz B, Vester U, Wingen AM , et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 2008; 12 (4) 474-478
• 36 Sagedal S, Nordal KP, Hartmann A , et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2 (9) 850-856
• 37 Reischig T, Jindra P, Svecová M, Kormunda S, Opatrný Jr K, Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 2006; 36 (2) 146-151
• 38 Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8 (5) 975-983
• 39 Humar A, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, Matas AJ. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68 (12) 1879-1883
• 40 Razonable RR, Rivero A, Rodriguez A , et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184 (11) 1461-1464
• 41 Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999; 68 (9) 1272-1279
• 42 Paraskeva M, Bailey M, Levvey BJ , et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011; 11 (10) 2190-2196
• 43 Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003; 75 (12) 2064-2068
• 44 Valantine HA, Gao SZ, Menon SG , et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100 (1) 61-66
• 45 Lemström K, Koskinen P, Krogerus L, Daemen M, Bruggeman C, Häyry P. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Circulation 1995; 92 (9) 2594-2604
• 46 Dickenmann MJ, Cathomas G, Steiger J, Mihatsch MJ, Thiel G, Tamm M. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 2001; 71 (6) 764-767
• 47 Chemaly RF, Yen-Lieberman B, Chapman J , et al. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant 2005; 5 (3) 544-548
• 48 Schlischewsky E, Fuehner T, Warnecke G , et al. Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients. Transpl Infect Dis 2013; 15 (1) 60-69
• 49 Bosch W, Heckman MG, Pungpapong S, Diehl NN, Shalev JA, Hellinger WC. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation 2012; 93 (7) 723-728
• 50 Rayes N, Seehofer D, Lullius SG , et al. Monitoring of human cytomegalovirus, HHV-6 and HHV-7 infection in kidney transplant recipients by molecular methods to predict HCMV disease after transplantation: a prospective study. Ann Transplant 2005; 10 (2) 23-28
• 51 Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355 (9220) 2032-2036
• 52 Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176 (6) 1484-1490
• 53 Kotton CN, Kumar D, Caliendo AM , et al; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89 (7) 779-795
• 54 Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. American Society of Transplantation Infectious Diseases Community of Practice; Canadian Society of Transplantation. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009; 9 (2) 258-268
• 55 Caliendo AM, Schuurman R, Yen-Lieberman B , et al; CMV Working Group of the Complications of HIV Disease RAC, AIDS Clinical Trials Group. Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma. J Clin Microbiol 2001; 39 (4) 1334-1338
• 56 Grim SA, Pereira E, Guzman G, Clark NM. CMV PCR as a diagnostic tool for CMV gastrointestinal disease after solid organ transplantation. Transplantation 2010; 90 (7) 799-801
• 57 Mazzulli T, Drew LW, Yen-Lieberman B , et al. Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol 1999; 37 (4) 958-963
• 58 Humar A, Mazzulli T, Moussa G , et al; Valganciclovir Solid Organ Transplant Study Group. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R− transplant recipients. Am J Transplant 2005; 5 (5) 1065-1070
• 59 Weber B, Fall EM, Berger A, Doerr HW. Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens. J Clin Virol 1999; 14 (3) 173-181
• 60 Pillay D, Ali AA, Liu SF, Kops E, Sweny P, Griffiths PD. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation 1993; 56 (1) 103-108
• 61 Buffone GJ, Frost A, Samo T, Demmler GJ, Cagle PT, Lawrence EC. The diagnosis of CMV pneumonitis in lung and heart/lung transplant patients by PCR compared with traditional laboratory criteria. Transplantation 1993; 56 (2) 342-347
• 62 Storch GA, Ettinger NA, Ockner D , et al. Quantitative cultures of the cell fraction and supernatant of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus pneumonitis in lung transplant recipients. J Infect Dis 1993; 168 (6) 1502-1506
• 63 Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 2004; 190 (6) 1076-1083
• 64 Cervera C, Lozano F, Linares L , et al. Influence of mannose-binding lectin gene polymorphisms on the invasiveness of cytomegalovirus disease after solid organ transplantation. Transplant Proc 2009; 41 (6) 2259-2261
• 65 Cervera C, Lozano F, Saval N , et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007; 83 (11) 1493-1500
• 66 Kwakkel-van Erp JM, Paantjens AW, van Kessel DA , et al. Mannose-binding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survival in lung transplantation. Clin Exp Immunol 2011; 165 (3) 410-416
• 67 Doron S, Ruthazer R, Werner BG, Rabson A, Snydman DR. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation 2006; 81 (5) 697-703
• 68 Goldfarb NS, Avery RK, Goormastic M , et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001; 71 (2) 242-246
• 69 Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012; 14 (6) 633-641
• 70 Asberg A, Humar A, Rollag H , et al; VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7 (9) 2106-2113
• 71 Asberg A, Humar A, Jardine AG , et al; VICTOR Study Group. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9 (5) 1205-1213
• 72 Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186 (6) 829-833
• 73 Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005; 7 (3-4) 166-170
• 74 Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356 (9230) 645-649
• 75 Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185 (1) 20-27
• 76 Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002; 34 (10) 1337-1341
• 77 Zuk DM, Humar A, Weinkauf JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010; 90 (6) 672-676
• 78 Avery RK, Marty FM, Strasfeld L , et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010; 12 (6) 489-496
• 79 Marschall M, Stamminger T, Urban A , et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother 2012; 56 (2) 1135-1137
• 80 Härter G, Michel D. Antiviral treatment of cytomegalovirus infection: an update. Expert Opin Pharmacother 2012; 13 (5) 623-627
• 81 Kaul DR, Stoelben S, Cober E , et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011; 11 (5) 1079-1084
• 82 Levi ME, Mandava N, Chan LK, Weinberg A, Olson JL. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8 (1) 38-43
• 83 Aspord C, Laurin D, Richard MJ, Vie H, Chaperot L, Plumas J. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases. Am J Transplant 2011; 11 (12) 2613-2626
• 84 Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43 (7) 869-880
• 85 Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4 (6) 928-936
• 86 Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21 (5) 547-554
• 87 Munoz-Price LS, Slifkin M, Ruthazer R , et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004; 39 (9) 1293-1299
• 88 Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008; 8 (1) 158-161
• 89 Snydman DR, Falagas ME, Avery R , et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc 2001; 33 (4) 2571-2575
• 90 Snydman DR, Werner BG, Dougherty NN , et al; Boston Center for Liver Transplantation CMVIG Study Group. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119 (10) 984-991
• 91 Zamora MR, Nicolls MR, Hodges TN , et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4 (10) 1635-1642
• 92 Humar A, Paya C, Pescovitz MD , et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R− solid organ transplant recipients. Am J Transplant 2004; 4 (4) 644-649
• 93 Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant 2008; 8 (8) 1749-1754
• 94 Griffiths PD, Stanton A, McCarrell E , et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011; 377 (9773) 1256-1263
• 95 Kharfan-Dabaja MA, Boeckh M, Wilck MB , et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12 (4) 290-299
• 96 Xu F, Sternberg MR, Kottiri BJ , et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296 (8) 964-973
• 97 Nahmias AJ, Roizman B. Infection with herpes-simplex viruses 1 and 2. 3. N Engl J Med 1973; 289 (15) 781-789
• 98 Corey L, Spear PG. Infections with herpes simplex viruses (1). N Engl J Med 1986; 314 (11) 686-691
• 99 Kimberlin DW, Rouse DJ. Clinical practice: genital herpes. N Engl J Med 2004; 350 (19) 1970-1977
• 100 Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003; 30 (2) 174-177
• 101 Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987; 316 (23) 1444-1449
• 102 Whitley RJ. Viral encephalitis. N Engl J Med 1990; 323 (4) 242-250
• 103 Kusne S, Schwartz M, Breinig MK , et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991; 163 (5) 1001-1007
• 104 Holland HK, Wingard JR, Saral R. Herpesvirus and enteric viral infections in bone marrow transplantation: clinical presentations, pathogenesis, and therapeutic strategies. Cancer Invest 1990; 8 (5) 509-521
• 105 Smyth RL, Higenbottam TW, Scott JP , et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation 1990; 49 (4) 735-739
• 106 Dummer JS, Armstrong J, Somers J , et al. Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis 1987; 155 (2) 202-206
• 107 Engelmann I, Hesse N, Fegbeutel C , et al. Incidence and impact of herpes simplex and cytomegalovirus detection in the respiratory tract after lung transplantation. Transpl Infect Dis 2011; 13 (3) 259-265
• 108 Singh N, Dummer JS, Kusne S , et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158 (1) 124-131
• 109 Engelmann I, Gottlieb J, Meier A , et al. Clinical relevance of and risk factors for HSV-related tracheobronchitis or pneumonia: results of an outbreak investigation. Crit Care 2007; 11 (6) R119
• 110 Lavery EA, Coyle WJ. Herpes simplex virus and the alimentary tract. Curr Gastroenterol Rep 2008; 10 (4) 417-423
• 111 Lafferty WE, Krofft S, Remington M , et al. Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high-prevalence population. J Clin Microbiol 1987; 25 (2) 323-326
• 112 Ramaswamy M, McDonald C, Smith M , et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex Transm Infect 2004; 80 (5) 406-410
• 113 Boivin G. Diagnosis of herpesvirus infections of the central nervous system. Herpes 2004; 11 (Suppl. 02) 48A-56A
• 114 Management of herpes virus infections following transplantation. J Antimicrob Chemother 2000; 45 (6) 729-748
• 115 Chou S, Gallagher JG, Merigan TC. Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. Lancet 1981; 1 (8235) 1392-1394
• 116 Tan HH, Goh CL. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol 2006; 7 (1) 13-29
• 117 Danve-Szatanek C, Aymard M, Thouvenot D , et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42 (1) 242-249
• 118 Sauerbrei A, Taut J, Zell R, Wutzler P. Resistance testing of clinical varicella-zoster virus strains. Antiviral Res 2011; 90 (3) 242-247
• 119 Sørensen GV, Rosthøj S, Würtz M, Danielsen TK, Schrøder H. The epidemiology of herpes zoster in 226 children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 57 (6) 993-997
• 120 Su SH, Martel-Laferrière V, Labbé AC , et al. High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17 (7) 1012-1017
• 121 Pergam SA, Forsberg CW, Boeckh MJ , et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis 2011; 13 (1) 15-23
• 122 Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV. PV16000 Study Group. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005; 192 (8) 1331-1339
• 123 Mustapic Z, Basic-Jukic N, Kes P , et al. Varicella zoster infection in renal transplant recipients: prevalence, complications and outcome. Kidney Blood Press Res 2011; 34 (6) 382-386
• 124 Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant 2008; 27 (1) 11-16
• 125 Gnann Jr JW, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002; 347 (5) 340-346
• 126 Chow J, Golan Y. Vaccination of solid-organ transplantation candidates. Clin Infect Dis 2009; 49 (10) 1550-1556
• 127 Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48 (Suppl. 01) S2-S7
• 128 Wiegering V, Schick J, Beer M , et al. Varicella-zoster virus infections in immunocompromised patients—a single centre 6-years analysis. BMC Pediatr 2011; 11: 31
• 129 Matsuzaki A, Suminoe A, Koga Y , et al. Fatal visceral varicella-zoster virus infection without skin involvement in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2008; 25 (3) 237-242
• 130 Buchbinder SP, Katz MH, Hessol NA , et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992; 166 (5) 1153-1156
• 131 Leung TF, Chik KW, Li CK , et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 25 (2) 167-172
• 132 Levitsky J, Kalil A, Meza JL, Hurst GE, Freifeld A. Herpes zoster infection after liver transplantation: a case-control study. Liver Transpl 2005; 11 (3) 320-325
• 133 Lévêque N, Galambrun C, Najioullah F, Bleyzac N, Pages MP, Bertrand Y. Two cases of varicella zoster virus meningitis found in pediatric patients after bone marrow transplantation despite valaciclovir prophylaxis and without skin lesions. J Med Virol 2006; 78 (4) 514-516
• 134 Brink AA, van Gelder M, Wolffs PF, Bruggeman CA, van Loo IH. Compartmentalization of acyclovir-resistant varicella zoster virus: implications for sampling in molecular diagnostics. Clin Infect Dis 2011; 52 (8) 982-987
• 135 Tarabishy AB, Khatib OF, Nocero JR, Budev M, Kaiser PK. Ocular complications in patients with lung transplants. Br J Ophthalmol 2011; 95 (9) 1295-1298
• 136 Lee MY, Kim KS, Lee WK. Intravitreal foscarnet for the treatment of acyclovir-resistant acute retinal necrosis caused by varicella zoster virus. Ocul Immunol Inflamm 2011; 19 (3) 212-213
• 137 Rogers JE, Cumpston A, Newton M, Craig M. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transpl Infect Dis 2011; 13 (5) 480-484
• 138 Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13 (3) 277-283
• 139 Kalpoe JS, Kroes AC, Verkerk S, Claas EC, Barge RM, Beersma MF. Clinical relevance of quantitative varicella-zoster virus (VZV) DNA detection in plasma after stem cell transplantation. Bone Marrow Transplant 2006; 38 (1) 41-46
• 140 Kim SJ, Kim K, Do YR, Bae SH, Yang DH, Lee JJ. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn J Clin Oncol 2011; 41 (3) 353-357
• 141 Fuks L, Shitrit D, Fox BD , et al. Herpes zoster after lung transplantation: incidence, timing, and outcome. Ann Thorac Surg 2009; 87 (2) 423-426
• 142 Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4 (1) 108-115
• 143 Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis 2008; 10 (4) 260-268
• 144 Herrero JI, Quiroga J, Sangro B , et al. Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl 2004; 10 (9) 1140-1143
• 145 Hsu RB, Fang CT, Chang SC , et al. Infectious complications after heart transplantation in Chinese recipients. Am J Transplant 2005; 5 (8) 2011-2016
• 146 Dworkin RH, Johnson RW, Breuer J , et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 (Suppl. 01) S1-S26
• 147 Hatchette T, Tipples GA, Peters G, Alsuwaidi A, Zhou J, Mailman TL. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatr Infect Dis J 2008; 27 (1) 75-77
• 148 Visse B, Dumont B, Huraux JM, Fillet AM. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis 1998; 178 (Suppl. 01) S55-S57
• 149 Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood 2006; 107 (5) 1800-1805
• 150 Erard V, Guthrie KA, Varley C , et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110 (8) 3071-3077
• 151 Oxman MN, Levin MJ, Johnson GR , et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352 (22) 2271-2284
• 152 Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010; 27 (2) 159-176
• 153 Löbermann M, Boršo D, Hilgendorf I, Fritzsche C, Zettl UK, Reisinger EC. Immunization in the adult immunocompromised host. Autoimmun Rev 2012; 11 (3) 212-218
• 154 Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 2008; 8 (1) 9-14
• 155 Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis 2008; 197 (Suppl. 02) S237-S241
• 156 Danzinger-Isakov L, Kumar D. AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 (Suppl. 04) S258-S262
• 157 Centers for Disease Control and Prevention, Infectious Disease Society of America. America Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49 (RR–10) 1-125
• 158 Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004; 4 (Suppl. 10) 160-163
• 159 Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996; 348 (9031) 858-861
• 160 Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332 (18) 1186-1191
• 161 De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005; 18 (1) 217-245
• 162 Dockrell DH. Human herpesvirus 6: molecular biology and clinical features. J Med Microbiol 2003; 52 (Pt 1) 5-18
• 163 Black JB, Pellett PE. Human herpesvirus 7. Rev Med Virol 1999; 9 (4) 245-262
• 164 Okuno T, Takahashi K, Balachandra K , et al. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol 1989; 27 (4) 651-653
• 165 Emery VC. Human herpesviruses 6 and 7 in solid organ transplant recipients. Clin Infect Dis 2001; 32 (9) 1357-1360
• 166 Michaelides A, Glare EM, Spelman DW , et al. beta-Herpesvirus (human cytomegalovirus and human herpesvirus 6) reactivation in at-risk lung transplant recipients and in human immunodeficiency virus-infected patients. J Infect Dis 2002; 186 (2) 173-180
• 167 Manuel O, Kumar D, Moussa G , et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009; 87 (5) 719-725
• 168 Lautenschlager I, Razonable RR. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. Transpl Int 2012; 25 (5) 493-502
• 169 Ariza-Heredia EJ, Razonable RR. Human herpes virus 8 in solid organ transplantation. Transplantation 2011; 92 (8) 837-844
• 170 Butler LM, Were WA, Balinandi S , et al. Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. J Infect Dis 2011; 203 (5) 625-634
• 171 Bergallo M, Costa C, Margio S , et al. Human herpes virus 8 infection in kidney transplant patients from an area of northwestern Italy (Piemonte region). Nephrol Dial Transplant 2007; 22 (6) 1757-1761
• 172 Einollahi B, Lessan-Pezeshki M, Nourbala MH , et al. Kaposi's sarcoma following living donor kidney transplantation: review of 7,939 recipients. Int Urol Nephrol 2009; 41 (3) 679-685
• 173 Gao SJ, Kingsley L, Li M , et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996; 2 (8) 925-928
• 174 Engels EA, Atkinson JO, Graubard BI , et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 2007; 196 (2) 199-207
• 175 Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338 (14) 948-954
• 176 Regamey N, Cathomas G, Schwager M, Wernli M, Harr T, Erb P. High human herpesvirus 8 seroprevalence in the homosexual population in Switzerland. J Clin Microbiol 1998; 36 (6) 1784-1786
• 177 Verbeek W, Frankel M, Miles S, Said J, Koeffler HP. Seroprevalence of HHV-8 antibodies in HIV-positive homosexual men without Kaposi's sarcoma and their clinical follow-up. Am J Clin Pathol 1998; 109 (6) 778-783
• 178 Cannon MJ, Dollard SC, Smith DK , et al; HIV Epidemiology Research Study Group. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. N Engl J Med 2001; 344 (9) 637-643
• 179 Luppi M, Barozzi P, Santagostino G , et al. Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood 2000; 96 (9) 3279-3281
• 180 Humar A, Asberg A, Kumar D , et al; VICTOR study group. An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant 2009; 9 (2) 374-381
• 181 Herbein G, Strasswimmer J, Altieri M, Woehl-Jaegle ML, Wolf P, Obert G. Longitudinal study of human herpesvirus 6 infection in organ transplant recipients. Clin Infect Dis 1996; 22 (1) 171-173
• 182 Humar A, Kumar D, Caliendo AM , et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation 2002; 73 (4) 599-604
• 183 Ljungman P, Singh N. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients. J Clin Virol 2006; 37 (Suppl. 01) S87-S91
• 184 Nash PJ, Avery RK, Tang WH, Starling RC, Taege AJ, Yamani MH. Encephalitis owing to human herpesvirus-6 after cardiac transplant. Am J Transplant 2004; 4 (7) 1200-1203
• 185 Singh N, Carrigan DR, Gayowski T, Singh J, Marino IR. Variant B human herpesvirus-6 associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient. Transplantation 1995; 60 (11) 1355-1357
• 186 Vu T, Carrum G, Hutton G, Heslop HE, Brenner MK, Kamble R. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39 (11) 705-709
• 187 Noguchi T, Yoshiura T, Hiwatashi A , et al. CT and MRI findings of human herpesvirus 6-associated encephalopathy: comparison with findings of herpes simplex virus encephalitis. AJR Am J Roentgenol 2010; 194 (3) 754-760
• 188 Seeley WW, Marty FM, Holmes TM , et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology 2007; 69 (2) 156-165
• 189 Other herpesviruses: HHV-6, HHV-7, HHV-8, HSV-1 and -2, VZV. Am J Transplant 2004; 4 (Suppl. 10) 66-71
• 190 Lautenschlager I, Linnavuori K, Höckerstedt K. Human herpesvirus-6 antigenemia after liver transplantation. Transplantation 2000; 69 (12) 2561-2566
• 191 Griffiths PD, Ait-Khaled M, Bearcroft CP , et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. J Med Virol 1999; 59 (4) 496-501
• 192 Costa C, Curtoni A, Bergallo M , et al. Quantitative detection of HHV-6 and HHV-7 in transbronchial biopsies from lung transplant recipients. New Microbiol 2011; 34 (3) 275-280
• 193 Luppi M, Barozzi P, Schulz TF , et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 2000; 343 (19) 1378-1385
• 194 Moosa MR. Kaposi's sarcoma in kidney transplant recipients: a 23-year experience. QJM 2005; 98 (3) 205-214
• 195 Al-Khader AA, Suleiman M, Al-Hasani M, Haleem A. Posttransplant Kaposi sarcoma: staging as a guide to therapy and prognosis. Nephron 1988; 48 (2) 165
• 196 Al Otaibi T, Al Sagheir A, Ludwin D, Meyer R. Post renal transplant Castleman's disease resolved after graft nephrectomy: a case report. Transplant Proc 2007; 39 (4) 1276-1277
• 197 Gaitonde S, Vidanovic V, Ni H. Concomitant and fatal HHV-8+ multicentric Castleman's disease and Kaposi's sarcoma in the same lymph node of an HIV- liver transplant patient. Histopathology 2007; 50 (7) 954-958
• 198 Lim EJ, Crowley P, Mitchell CA, Angus PW. Post-liver transplantation multicentric Castleman disease treated with valganciclovir and weaning of immunosuppression. Am J Transplant 2011; 11 (1) 169-172
• 199 Boulanger E, Afonso PV, Yahiaoui Y, Adle-Biassette H, Gabarre J, Agbalika F. Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant 2008; 8 (3) 707-710
• 200 Dotti G, Fiocchi R, Motta T , et al. Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia 1999; 13 (5) 664-670
• 201 Jones D, Ballestas ME, Kaye KM , et al. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med 1998; 339 (7) 444-449
• 202 Lautenschlager I, Razonable RR. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. Transpl Int 2012; 25 (5) 493-502
• 203 Boutolleau D, Duros C, Bonnafous P , et al. Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. J Clin Virol 2006; 35 (3) 257-263
• 204 Safronetz D, Humar A, Tipples GA. Differentiation and quantitation of human herpesviruses 6A, 6B and 7 by real-time PCR. J Virol Methods 2003; 112 (1-2) 99-105
• 205 Tedeschi R, Marus A, Bidoli E, Simonelli C, De Paoli P. Human herpesvirus 8 DNA quantification in matched plasma and PBMCs samples of patients with HHV8-related lymphoproliferative diseases. J Clin Virol 2008; 43 (3) 255-259
• 206 Tedeschi R, Enbom M, Bidoli E, Linde A, De Paoli P, Dillner J. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol 2001; 39 (12) 4269-4273
• 207 De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001; 11 (6) 381-395
• 208 Ljungman P. Beta-herpesvirus challenges in the transplant recipient. J Infect Dis 2002; 186 (Suppl. 01) S99-S109
• 209 Brennan DC, Storch GA, Singer GG, Lee L, Rueda J, Schnitzler MA. The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir. J Infect Dis 2000; 181 (5) 1557-1561
• 210 Wang FZ, Dahl H, Linde A, Brytting M, Ehrnst A, Ljungman P. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood 1996; 88 (9) 3615-3620
• 211 Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009; 87 (2) 157-163
• 212 Régnier-Rosencher E, Barrou B, Marcelin AG , et al. Primary effusion lymphoma in two kidney transplant recipients [in French]. Ann Dermatol Venereol 2010; 137 (4) 285-289
• 213 Nourse JP, Jones K, Gandhi MK. Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant 2011; 11 (5) 888-895
• 214 Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29-44
• 215 Preiksaitis JK. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis 2004; 39 (7) 1016-1023
• 216 Weigt SSLL, Fishbein MC, Lynch III JP. Lymphoproliferative disorders complicating solid organ transplantation. In: Lynch III JP, Ross DJ, , eds. Lung and Heart-Lung Transplantation. New York, NY: Taylor & Francis; 2006. 217. 901-934
• 217 Ramalingam P, Rybicki L, Smith MD , et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol 2002; 15 (6) 647-656
• 218 Ziarkiewicz-Wróblewska B, Górnicka B, Ołdakowska U , et al. Plasmacytic hyperplasia—the early form of posttransplant lymphoproliferative disorder—with atypical morphology and clinical course in patient after liver transplantation: a case report. Transplant Proc 2003; 35 (6) 2320-2322
• 219 Zamora MR. DNA viruses (CMV, EBV, and the herpesviruses). Semin Respir Crit Care Med 2011; 32 (4) 454-470
• 220 Lundell R, Elenitoba-Johnson KS, Lim MS. T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient. Am J Surg Pathol 2004; 28 (7) 967-973
• 221 Sebire NJ, Malone M, Ramsay AD. Posttransplant lymphoproliferative disorder presenting as CD30+, ALK+, anaplastic large cell lymphoma in a child. Pediatr Dev Pathol 2004; 7 (3) 290-293
• 222 Bustillo M, Perez Melon C, Otero Glz A , et al. High grade lymphoma in a post-renal transplant patient. Description of a case and literature review. Nephron 2000; 84 (2) 189-191
• 223 Orjuela MA, Alobeid B, Liu X , et al. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. Br J Haematol 2011; 152 (6) 733-742
• 224 Maecker B, Jack T, Zimmermann M , et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007; 25 (31) 4902-4908
• 225 Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4 (2) 222-230
• 226 Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343 (7) 481-492
• 227 Crawford DH, Macsween KF, Higgins CD , et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 2006; 43 (3) 276-282
• 228 Gulley ML, Swinnen LJ, Plaisance Jr KT, Schnell C, Grogan TM, Schneider BG. Southwest Oncology Group. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 2003; 76 (6) 959-964
• 229 Verschuuren E, van der Bij W, de Boer W, Timens W, Middeldorp J, The TH. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease. J Med Virol 2003; 69 (2) 258-266
• 230 Holman CJ, Karger AB, Mullan BD, Brundage RC, Balfour Jr HH. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant 2012; 26 (5) 741-747
• 231 Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?. Transplantation 2003; 76 (6) 984-988
• 232 Wigle DA, Chaparro C, Humar A, Hutcheon MA, Chan CK, Keshavjee S. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation 2001; 72 (11) 1783-1786
• 233 Hachem RR, Chakinala MM, Yusen RD , et al. Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome. Transplantation 2004; 77 (3) 431-437
• 234 Paranjothi S, Yusen RD, Kraus MD, Lynch JP, Patterson GA, Trulock EP. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant 2001; 20 (10) 1054-1063
• 235 Siegel MJ, Lee EY, Sweet SC, Hildebolt C. CT of posttransplantation lymphoproliferative disorder in pediatric recipients of lung allograft. AJR Am J Roentgenol 2003; 181 (4) 1125-1131
• 236 Angel LF, Cai TH, Sako EY, Levine SM. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center. Ann Transplant 2000; 5 (3) 26-30
• 237 Lim GY, Newman B, Kurland G, Webber SA. Posttransplantation lymphoproliferative disorder: manifestations in pediatric thoracic organ recipients. Radiology 2002; 222 (3) 699-708
• 238 Pickhardt PJ, Siegel MJ. Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology 1999; 213 (1) 73-78
• 239 Armitage JM, Kormos RL, Stuart RS , et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10 (6) 877-886 , discussion 886–887
• 240 Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124 (4) 1242-1249
• 241 Gong JZ, Stenzel TT, Bennett ER , et al. Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. Am J Surg Pathol 2003; 27 (6) 818-827
• 242 Swerdlow SHWS, Chadburn A, Ferry JA. Post-transplant lymphopliferative disorders. In: WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008: 343-349
• 243 Tsai DE, Douglas L, Andreadis C , et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 2008; 8 (5) 1016-1024
• 244 Bordon V, Padalko E, Benoit Y, Dhooge C, Laureys G. Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation. Pediatr Transplant 2012; 16 (2) 144-150
• 245 Rappaport DC, Chamberlain DW, Shepherd FA, Hutcheon MA. Lymphoproliferative disorders after lung transplantation: imaging features. Radiology 1998; 206 (2) 519-524
• 246 Scarsbrook AF, Warakaulle DR, Dattani M, Traill Z. Post-transplantation lymphoproliferative disorder: the spectrum of imaging appearances. Clin Radiol 2005; 60 (1) 47-55
• 247 Marom EM, McAdams HP, Butnor KJ, Coleman RE. Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. J Thorac Imaging 2004; 19 (2) 74-78
• 248 Wong JY, Tait B, Levvey B , et al. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease. Transplantation 2004; 78 (2) 205-210
• 249 Aris RM, Maia DM, Neuringer IP , et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med 1996; 154 (6 Pt 1) 1712-1717
• 250 Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol Dial Transplant 2012; 27 (7) 2971-2979
• 251 Gao SZ, Chaparro SV, Perlroth M , et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003; 22 (5) 505-514
• 252 Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant 2004; 8 (3) 267-272
• 253 Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76 (9) 1289-1293
• 254 Manlhiot C, Pollock-Barziv SM, Holmes C , et al. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transplant 2010; 29 (6) 648-657
• 255 Duvoux C, Pageaux GP, Vanlemmens C , et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002; 74 (8) 1103-1109
• 256 Swinnen LJ, Costanzo-Nordin MR, Fisher SG , et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323 (25) 1723-1728
• 257 Worth A, Conyers R, Cohen J , et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol 2011; 155 (3) 377-385
• 258 Saueressig MG, Boussaud V, Amrein C, Guillemain R, Souilamas J, Souilamas R. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. Clin Transplant 2011; 25 (4) E430-E436
• 259 Soler MJ, Puig JM, Mir M , et al. Posttransplant lymphoproliferative disease: treatment and outcome in renal transplant recipients. Transplant Proc 2003; 35 (5) 1709-1713
• 260 Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol 2004; 40 (5) 728-735
• 261 Fernández MC, Bes D, De Dávila M , et al. Post-transplant lymphoproliferative disorder after pediatric liver transplantation: characteristics and outcome. Pediatr Transplant 2009; 13 (3) 307-310
• 262 Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B. T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. Br J Haematol 2004; 127 (4) 429-432
• 263 Aull MJ, Buell JF, Trofe J , et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation 2004; 78 (11) 1676-1682
• 264 Krumbholz A, Sandhaus T, Göhlert A , et al. Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient. Med Microbiol Immunol (Berl) 2010; 199 (4) 317-322
• 265 Engelmann I, Welte T, Fühner T , et al. Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation. J Clin Virol 2009; 45 (1) 47-53
• 266 Neurohr C, Huppmann P, Leuchte H , et al; Munich Lung Transplant Group. Human herpesvirus 6 in bronchoalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome?. Am J Transplant 2005; 5 (12) 2982-2991
• 267 Caillard S, Lamy FX, Quelen C , et al; French Transplant Centers. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012; 12 (3) 682-693
• 268 Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86 (9) 3333-3340
• 269 Verschuuren EA, Stevens SJ, van Imhoff GW , et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002; 73 (1) 100-104
• 270 Evens AM, David KA, Helenowski I , et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28 (6) 1038-1046
• 271 Oton AB, Wang H, Leleu X , et al. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma 2008; 49 (9) 1738-1744
• 272 Chan TS, Hwang YY, Gill H , et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin Transplant 2012; 26 (5) 679-683
• 273 Sherritt MA, Bharadwaj M, Burrows JM , et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 2003; 75 (9) 1556-1560
• 274 Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11 (5) 383-392
• 275 Doubrovina E, Oflaz-Sozmen B, Prockop SE , et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119 (11) 2644-2656
• 276 Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5 (12) 2894-2900
• 277 Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis 2003; 3 (10) 611-623
• 278 Kazory A, Ducloux D. Renal transplantation and polyomavirus infection: recent clinical facts and controversies. Transpl Infect Dis 2003; 5 (2) 65-71
• 279 Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 2010; 89 (9) 1057-1070
• 280 Renoult E, Coutlée F, Pâquet M , et al. Evaluation of a preemptive strategy for BK polyomavirus-associated nephropathy based on prospective monitoring of BK viremia: a kidney transplantation center experience. Transplant Proc 2010; 42 (10) 4083-4087
• 281 Dropulic LK, Jones RJ. Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant 2008; 41 (1) 11-18
• 282 Cesaro S, Hirsch HH, Faraci M , et al; European Group for Blood and Marrow Transplantation. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis 2009; 49 (2) 233-240
• 283 Khan H, Oberoi S, Mahvash A , et al. Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. Biol Blood Marrow Transplant 2011; 17 (10) 1551-1555
• 284 Brennan DC, Agha I, Bohl DL , et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5 (3) 582-594
• 285 Bressollette-Bodin C, Coste-Burel M, Hourmant M, Sebille V, Andre-Garnier E, Imbert-Marcille BM. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant 2005; 5 (8) 1926-1933
• 286 Cesaro S, Facchin C, Tridello G , et al. A prospective study of BK-virus-associated haemorrhagic cystitis in paediatric patients undergoing allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41 (4) 363-370
• 287 Doucette KE, Pang XL, Jackson K , et al. Prospective monitoring of BK polyomavirus infection early posttransplantation in nonrenal solid organ transplant recipients. Transplantation 2008; 85 (12) 1733-1736
• 288 Muñoz P, Fogeda M, Bouza E, Verde E, Palomo J, Bañares R. BKV Study Group. Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect Dis 2005; 41 (12) 1720-1725
• 289 Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV. PV16000 Study Group. A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis 2005; 192 (8) 1349-1354
• 290 Amir A, Shapiro R, Shulman LM , et al. BK virus infection and its effect on renal function in pediatric liver-transplant recipients: a cross-sectional, longitudinal, prospective study. Transplantation 2011; 92 (8) 943-946
• 291 Thomas LD, Milstone AP, Vilchez RA, Zanwar P, Butel JS, Dummer JS. Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation. Transplantation 2009; 88 (3) 360-366
• 292 Thomas LD, Vilchez RA, White ZS , et al. A prospective longitudinal study of polyomavirus shedding in lung-transplant recipients. J Infect Dis 2007; 195 (3) 442-449
• 293 Purighalla R, Shapiro R, McCauley J, Randhawa P. BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 1995; 26 (4) 671-673
• 294 Hirsch HH, Knowles W, Dickenmann M , et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347 (7) 488-496
• 295 Hirsch HH, Brennan DC, Drachenberg CB , et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79 (10) 1277-1286
• 296 Randhawa PS, Demetris AJ. Nephropathy due to polyomavirus type BK. N Engl J Med 2000; 342 (18) 1361-1363
• 297 Egli A, Helmersen DS, Taub K, Hirsch HH, Johnson A. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. Am J Transplant 2010; 10 (10) 2324-2330
• 298 Gorczynska E, Turkiewicz D, Rybka K , et al. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11 (10) 797-804
• 299 Drachenberg CB, Papadimitriou JC, Ramos E. Histologic versus molecular diagnosis of BK polyomavirus-associated nephropathy: a shifting paradigm?. Clin J Am Soc Nephrol 2006; 1 (3) 374-379
• 300 Limaye AP, Smith KD, Cook L , et al. Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant 2005; 5 (3) 614-620
• 301 Schmid H, Burg M, Kretzler M, Banas B, Gröne HJ, Kliem V. BK virus associated nephropathy in native kidneys of a heart allograft recipient. Am J Transplant 2005; 5 (6) 1562-1568
• 302 Barber CE, Hewlett TJ, Geldenhuys L, Kiberd BA, Acott PD, Hatchette TF. BK virus nephropathy in a heart transplant recipient: case report and review of the literature. Transpl Infect Dis 2006; 8 (2) 113-121
• 303 Haririan A, Ramos ER, Drachenberg CB, Weir MR, Klassen DK. Polyomavirus nephropathy in native kidneys of a solitary pancreas transplant recipient. Transplantation 2002; 73 (8) 1350-1353
• 304 Schwarz A, Mengel M, Haller H, Niedermeyer J. Polyoma virus nephropathy in native kidneys after lung transplantation. Am J Transplant 2005; 5 (10) 2582-2585
• 305 Elidemir O, Chang IF, Schecter MG, Mallory GB. BK virus-associated hemorrhagic cystitis in a pediatric lung transplant recipient. Pediatr Transplant 2007; 11 (7) 807-810
• 306 Schaub S, Hirsch HH, Dickenmann M , et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 2010; 10 (12) 2615-2623
• 307 Hilton R, Tong CY. Antiviral therapy for polyomavirus-associated nephropathy after renal transplantation. J Antimicrob Chemother 2008; 62 (5) 855-859
• 308 Saad ER, Bresnahan BA, Cohen EP , et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 2008; 85 (6) 850-854
• 309 Williams JW, Javaid B, Kadambi PV , et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005; 352 (11) 1157-1158
• 310 Liacini A, Seamone ME, Muruve DA, Tibbles LA. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation 2010; 90 (12) 1450-1457
• 311 Faraci M, Cuzzubbo D, Lanino E , et al. Low dosage cidofovir without probenecid as treatment for BK virus hamorrhagic cystitis after hemopoietic stem cell transplant. Pediatr Infect Dis J 2009; 28 (1) 55-57
• 312 Sener A, House AA, Jevnikar AM , et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 2006; 81 (1) 117-120
• 313 Chang CY, Gangji A, Chorneyko K, Kapoor A. Urological manifestations of BK polyomavirus in renal transplant recipients. Can J Urol 2005; 12 (5) 2829-2836
• 314 Mateen FJ, Muralidharan R, Carone M , et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011; 70 (2) 305-322
• 315 Bellizzi A, Nardis C, Anzivino E , et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol 2012; 18 (1) 1-11
• 316 Ouwens JP, Haaxma-Reiche H, Verschuuren EA , et al; Groningen Lung Transplant Group. Visual symptoms after lung transplantation: a case of progressive multifocal leukoencephalopathy. Transpl Infect Dis 2000; 2 (1) 29-32
• 317 Aksamit AJ. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist 2006; 12 (6) 293-298
• 318 Tavazzi E, Ferrante P, Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect 2011; 17 (12) 1776-1780
• 319 Egli A, Infanti L, Dumoulin A , et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199 (6) 837-846
• 320 Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186 (Suppl. 02) S180-S186
• 321 Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9 (4) 425-437
• 322 Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009; 9 (10) 625-636
• 323 Delbue S, Branchetti E, Boldorini R , et al. Presence and expression of JCV early gene large T Antigen in the brains of immunocompromised and immunocompetent individuals. J Med Virol 2008; 80 (12) 2147-2152
• 324 Tan CS, Dezube BJ, Bhargava P , et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 2009; 199 (6) 881-888
• 325 Chapagain ML, Nerurkar VR. Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 2010; 202 (2) 184-191
• 326 Maginnis MS, Atwood WJ. JC virus: an oncogenic virus in animals and humans?. Semin Cancer Biol 2009; 19 (4) 261-269
• 327 Wenning W, Haghikia A, Laubenberger J , et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009; 361 (11) 1075-1080
• 328 Del Valle L, White MK, Khalili K. Potential mechanisms of the human polyomavirus JC in neural oncogenesis. J Neuropathol Exp Neurol 2008; 67 (8) 729-740
• 329 Kantarci G, Eren Z, Demirağ A, Dogan I, Cakalagaoglu F, Yilmaz G. JC virus-associated nephropathy in a renal transplant recipient and comparative analysis of previous cases. Transpl Infect Dis 2011; 13 (1) 89-92
• 330 Randhawa P, Baksh F, Aoki N, Tschirhart D, Finkelstein S. JC virus infection in allograft kidneys: analysis by polymerase chain reaction and immunohistochemistry. Transplantation 2001; 71 (9) 1300-1303
• 331 Gardner SD, MacKenzie EF, Smith C, Porter AA. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol 1984; 37 (5) 578-586
• 332 Sahraian MA, Radue EW, Eshaghi A, Besliu S, Minagar A. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol 2012; 19 (8) 1060-1069
• 333 Khanna N, Elzi L, Mueller NJ , et al; Swiss HIV Cohort Study. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009; 48 (10) 1459-1466
• 334 Christensen KL, Holman RC, Hammett TA, Belay ED, Schonberger LB. Progressive multifocal leukoencephalopathy deaths in the USA, 1979-2005. Neuroepidemiology 2010; 35 (3) 178-184
• 335 Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010; 75 (15) 1326-1332
• 336 García-Suárez J, de Miguel D, Krsnik I, Bañas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80 (4) 271-281
• 337 Carson KR, Focosi D, Major EO , et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10 (8) 816-824
• 338 Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009; 60 (12) 3761-3765
• 339 Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010; 33 (11) 969-983
• 340 Carson KR, Evens AM, Richey EA , et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113 (20) 4834-4840
• 341 Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61: 35-47
• 342 Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77 (11) 1061-1067
• 343 Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9 (4) 438-446
• 344 Keene DL, Legare C, Taylor E, Gallivan J, Cawthorn GM, Vu D. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci 2011; 38 (4) 565-571
• 345 Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal Pan G. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011; 65 (3) 546-551
• 346 Neff RT, Hurst FP, Falta EM , et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008; 86 (10) 1474-1478
• 347 Shitrit D, Nirit L, Shiran SI , et al. Progressive multifocal leukoencephalopathy in a lung transplant recipient. J Heart Lung Transplant 2003; 22 (8) 946-950
• 348 Waggoner J, Martinu T, Palmer SM. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 2009; 28 (4) 395-398
• 349 Drachenberg CB, Hirsch HH, Papadimitriou JC , et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation 2007; 84 (3) 323-330
• 350 Focosi D, Marco T, Kast RE, Maggi F, Ceccherini-Nelli L, Petrini M. Progressive multifocal leukoencephalopathy: what's new?. Neuroscientist 2010; 16 (3) 308-323
• 351 Berenguer J, Miralles P, Arrizabalaga J , et al; GESIDA 11/99 Study Group. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36 (8) 1047-1052
• 352 De Luca A, Ammassari A, Pezzotti P , et al; Gesida 9/99, IRINA, ACTG 363 Study Groups. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 2008; 22 (14) 1759-1767
• 353 Hall CD, Dafni U, Simpson D , et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998; 338 (19) 1345-1351
• 354 Verma S, Cikurel K, Koralnik IJ , et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 2007; 196 (5) 709-711
• 355 Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009; 66 (2) 255-258
• 356 Brickelmaier M, Lugovskoy A, Kartikeyan R , et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53 (5) 1840-1849
• 357 Focosi D, Fazzi R, Montanaro D, Emdin M, Petrini M. Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: a clinical, neuroradiological and virological response after treatment with risperidone. Antiviral Res 2007; 74 (2) 156-158
• 358 Buckanovich RJ, Liu G, Stricker C , et al. Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy. Ann Hematol 2002; 81 (7) 410-413
• 359 Moenster RP, Jett RA. Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. Am J Health Syst Pharm 2012; 69 (6) 496-498
• 360 Henquell C, Boeuf B, Mirand A , et al. Fatal adenovirus infection in a neonate and transmission to health-care workers. J Clin Virol 2009; 45 (4) 345-348
• 361 Lynch III JP, Fishbein M, Echavarria M. Adenovirus. Semin Respir Crit Care Med 2011; 32 (4) 494-511
• 362 Lee J, Choi EH, Lee HJ. Comprehensive serotyping and epidemiology of human adenovirus isolated from the respiratory tract of Korean children over 17 consecutive years (1991-2007). J Med Virol 2010; 82 (4) 624-631
• 363 Kajon AE, Lu X, Erdman DD , et al. Molecular epidemiology and brief history of emerging adenovirus 14-associated respiratory disease in the United States. J Infect Dis 2010; 202 (1) 93-103
• 364 Houng HS, Gong H, Kajon AE , et al. Genome sequences of human adenovirus 14 isolates from mild respiratory cases and a fatal pneumonia, isolated during 2006-2007 epidemics in North America. Respir Res 2010; 11: 116
• 365 Kajon AE, Dickson LM, Metzgar D, Houng HS, Lee V, Tan BH. Outbreak of febrile respiratory illness associated with adenovirus 11a infection in a Singapore military training cAMP. J Clin Microbiol 2010; 48 (4) 1438-1441
• 366 Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43 (3) 331-339
• 367 Chang SY, Lee CN, Lin PH , et al. A community-derived outbreak of adenovirus type 3 in children in Taiwan between 2004 and 2005. J Med Virol 2008; 80 (1) 102-112
• 368 Echavarría M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 2008; 21 (4) 704-715
• 369 Kim Y-J, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med 2007; 28 (2) 222-242
• 370 Yeung R, Eshaghi A, Lombos E , et al. Characterization of culture-positive adenovirus serotypes from respiratory specimens in Toronto, Ontario, Canada: September 2007-June 2008. Virol J 2009; 6: 11
• 371 Moura PO, Roberto AF, Hein N , et al. Molecular epidemiology of human adenovirus isolated from children hospitalized with acute respiratory infection in São Paulo, Brazil. J Med Virol 2007; 79 (2) 174-181
• 372 Chen HL, Chiou SS, Hsiao HP , et al. Respiratory adenoviral infections in children: a study of hospitalized cases in southern Taiwan in 2001–2002. J Trop Pediatr 2004; 50 (5) 279-284
• 373 Russell KL, Hawksworth AW, Ryan MA , et al. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004. Vaccine 2006; 24 (15) 2835-2842
• 374 Zheng X, Lu X, Erdman DD , et al. Identification of adenoviruses from high risk pediatric stem cell transplant recipients and controls. J Clin Microbiol 2007; 46 (1) 317-320
• 375 Bil-Lula I, Ussowicz M, Rybka B , et al. Hematuria due to adenoviral infection in bone marrow transplant recipients. Transplant Proc 2010; 42 (9) 3729-3734
• 376 Chemaly RF, Ghosh S, Bodey GP , et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006; 85 (5) 278-287
• 377 Lessa FC, Gould PL, Pascoe N , et al. Health care transmission of a newly emergent adenovirus serotype in health care personnel at a military hospital in Texas, 2007. J Infect Dis 2009; 200 (11) 1759-1765
• 378 Russell KL, Broderick MP, Franklin SE , et al. Transmission dynamics and prospective environmental sampling of adenovirus in a military recruit setting. J Infect Dis 2006; 194 (7) 877-885
• 379 Leruez-Ville M, Chardin-Ouachée M, Neven B , et al. Description of an adenovirus A31 outbreak in a paediatric haematology unit. Bone Marrow Transplant 2006; 38 (1) 23-28
• 380 Mattner F, Sykora KW, Meissner B, Heim A. An adenovirus type F41 outbreak in a pediatric bone marrow transplant unit: analysis of clinical impact and preventive strategies. Pediatr Infect Dis J 2008; 27 (5) 419-424
• 381 Ishiko H, Aoki K. Spread of epidemic keratoconjunctivitis due to a novel serotype of human adenovirus in Japan. J Clin Microbiol 2009; 47 (8) 2678-2679
• 382 Sdiri-Loulizi K, Gharbi-Khelifi H, de Rougemont A , et al. Molecular epidemiology of human astrovirus and adenovirus serotypes 40/41 strains related to acute diarrhea in Tunisian children. J Med Virol 2009; 81 (11) 1895-1902
• 383 Hakim FA, Tleyjeh IM. Severe adenovirus pneumonia in immunocompetent adults: a case report and review of the literature. Eur J Clin Microbiol Infect Dis 2008; 27 (2) 153-158
• 384 Hamada N, Gotoh K, Hara K , et al. Nosocomial outbreak of epidemic keratoconjunctivitis accompanying environmental contamination with adenoviruses. J Hosp Infect 2008; 68 (3) 262-268
• 385 Filho EP, da Costa Faria NR, Fialho AM , et al. Adenoviruses associated with acute gastroenteritis in hospitalized and community children up to 5 years old in Rio de Janeiro and Salvador, Brazil. J Med Microbiol 2007; 56 (Pt 3) 313-319
• 386 Symeonidis N, Jakubowski A, Pierre-Louis S , et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis 2007; 9 (2) 108-113
• 387 Yokose N, Hirakawa T, Inokuchi K. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib. Leuk Res 2009; 33 (8) e106
• 388 Fanourgiakis P, Georgala A, Vekemans M , et al. Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient. Clin Infect Dis 2005; 40 (1) 199-201
• 389 Ferreira GF, Oliveira RA, Lucon M , et al. Hemorrhagic cystitis secondary to adenovirus or herpes simplex virus infection following renal transplantation: four case reports. Transplant Proc 2009; 41 (10) 4416-4419
• 390 Keswani M, Moudgil A. Adenovirus-associated hemorrhagic cystitis in a pediatric renal transplant recipient. Pediatr Transplant 2007; 11 (5) 568-571
• 391 Mori K, Yoshihara T, Nishimura Y , et al. Acute renal failure due to adenovirus-associated obstructive uropathy and necrotizing tubulointerstitial nephritis in a bone marrow transplant recipient. Bone Marrow Transplant 2003; 31 (12) 1173-1176
• 392 Sujeet K, Vasudev B, Desai P , et al. Acute kidney injury requiring dialysis secondary to adenovirus nephritis in renal transplant recipient. Transpl Infect Dis 2011; 13 (2) 174-177
• 393 Bruno B, Zager RA, Boeckh MJ , et al. Adenovirus nephritis in hematopoietic stem-cell transplantation. Transplantation 2004; 77 (7) 1049-1057
• 394 Bowles NE, Ni J, Kearney DL , et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003; 42 (3) 466-472
• 395 Gray GC, McCarthy T, Lebeck MG , et al. Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006. Clin Infect Dis 2007; 45 (9) 1120-1131
• 396 Melón S, Méndez S, Iglesias B , et al. Involvement of adenovirus in clinical mononucleosis-like syndromes in young children. Eur J Clin Microbiol Infect Dis 2005; 24 (5) 314-318
• 397 Robin M, Marque-Juillet S, Scieux C , et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica 2007; 92 (9) 1254-1257
• 398 Kroes AC, de Klerk EP, Lankester AC , et al. Sequential emergence of multiple adenovirus serotypes after pediatric stem cell transplantation. J Clin Virol 2007; 38 (4) 341-347
• 399 de Mezerville MH, Tellier R, Richardson S, Hébert D, Doyle J, Allen U. Adenoviral infections in pediatric transplant recipients: a hospital-based study. Pediatr Infect Dis J 2006; 25 (9) 815-818
• 400 Sivaprakasam P, Carr TF, Coussons M , et al. Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention. J Pediatr Hematol Oncol 2007; 29 (2) 81-85
• 401 Neofytos D, Ojha A, Mookerjee B , et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007; 13 (1) 74-81
• 402 Erard V, Huang ML, Ferrenberg J , et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. Clin Infect Dis 2007; 45 (8) 958-965
• 403 Sujeet K, Vasudev B, Desai P , et al. Acute kidney injury requiring dialysis secondary to adenovirus nephritis in renal transplant recipient. Transpl Infect Dis 2011; 13 (2) 174-177
• 404 Humar A, Kumar D, Mazzulli T , et al; PV16000 Study Group. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant 2005; 5 (10) 2555-2559
• 405 Moulik M, Breinholt JP, Dreyer WJ , et al. Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients. J Am Coll Cardiol 2010; 56 (7) 582-592
• 406 Shirali GS, Ni J, Chinnock RE , et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 2001; 344 (20) 1498-1503
• 407 Ohori NP, Michaels MG, Jaffe R, Williams P, Yousem SA. Adenovirus pneumonia in lung transplant recipients. Hum Pathol 1995; 26 (10) 1073-1079
• 408 Bridges ND, Spray TL, Collins MH, Bowles NE, Towbin JA. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg 1998; 116 (4) 617-623
• 409 Simsir A, Greenebaum E, Nuovo G, Schulman LL. Late fatal adenovirus pneumonitis in a lung transplant recipient. Transplantation 1998; 65 (4) 592-594
• 410 Naesens L, Lenaerts L, Andrei G , et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 2005; 49 (3) 1010-1016
• 411 Yusuf U, Hale GA, Carr J , et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006; 81 (10) 1398-1404
• 412 Doan ML, Mallory GB, Kaplan SL , et al. Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant 2007; 26 (9) 883-889
• 413 Walls T, Hawrami K, Ushiro-Lumb I, Shingadia D, Saha V, Shankar AG. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary?. Clin Infect Dis 2005; 40 (9) 1244-1249
• 414 Heemskerk B, Lankester AC, van Vreeswijk T , et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis 2005; 191 (4) 520-530
• 415 Sauerbrei A, Sehr K, Brandstädt A, Heim A, Reimer K, Wutzler P. Sensitivity of human adenoviruses to different groups of chemical biocides. J Hosp Infect 2004; 57 (1) 59-66
• 416 Trei JS, Johns NM, Garner JL , et al. Spread of adenovirus to geographically dispersed military installations, May-October 2007. Emerg Infect Dis 2010; 16 (5) 769-775